hackint0sh/New-Dataset huggingface dataset:
Researchers will compare intestinal and peripheral leukocytes before and after the drug's administration. conditions: Ulcerative Colitis conditions: Ulcerative Colitis Chronic Moderate studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ESTIMATED measure: difference in leukocyte subsets sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California San Diego status: RECRUITING city: San Diego state: California zip: 92093-006 country: United States name: Jesus Rivera-Nieves, MD role: CONTACT phone: 858-534-5495 email: jriveran@ucsd.edu lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06311110 id: #BC-11326 AM04 briefTitle: Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-30 date: 2024-02-08 date: 2024-06-30 date: 2024-03-15 date: 2024-03-15 name: University Hospital, Ghent class: OTHER briefSummary: This cross-sectional case-control study aimed to determine whether there is a significant difference in the prevalence of impaired toilet training, LUTS, and functional bowel problems among children diagnosed with DCD and typically developing children (TDC). conditions: Developmental Coordination Disorder conditions: Lower Urinary Tract Symptoms conditions: Bowel Dysfunction studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 84 type: ESTIMATED name: Vancouver symptom score for dysfunctional elimination symptoms Questionnaire name: Developmental Coordination Disorder Questionnaire name: Questionnaire concerning impaired toilettraining and comorbities measure: Impaired toilet training measure: Daytime incontinence measure: Enuresis measure: Fecal incontinence measure: Toilet training difficulties measure: General bladder and bowel dysfunction sex: ALL minimumAge: 5 Years maximumAge: 8 Years stdAges: CHILD facility: Ghent University Hospital/Ghent University city: Ghent state: East Flanders zip: 9000 country: Belgium lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06311097 id: M402 briefTitle: Dairy Products to Your Gut and Brain acronym: YourGutBrain overallStatus: RECRUITING date: 2024-04-08 date: 2025-09 date: 2025-09 date: 2024-03-15 date: 2024-04-15 name: University of Copenhagen class: OTHER name: University of Aarhus name: APC Microbiome Ireland briefSummary: The goal of this intervention study is to compare the effects of fermented dairy and non-fermented dairy on bowel habits and cognitive performance in healthy women with defecations every other day or less. Furthermore, the study aims to explore underlying mechanisms linking the gut and the brain.
In addition, a sub-study will be conducted to explore differences in gut and brain measures between women with daily (reference group) and few (intervention group) weekly bowel movements, respectively, and to explore associations between measures of gut- and brain function. conditions: Healthy conditions: Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Two 4-week intervention periods separated by a washout period of at least 4 weeks.
nctId: NCT06311084 id: 310211 briefTitle: IMAGINATOR 2.0: Co-design and Early Evaluation of a Novel Blended Digital Intervention Targeting Self-harm in Young People acronym: IMAG2 overallStatus: COMPLETED date: 2022-11-25 date: 2023-11-09 date: 2024-01-23 date: 2024-03-15 date: 2024-04-04 name: Imperial College London class: OTHER name: National Institute for Health Research, United Kingdom briefSummary: This study aims to investigate acceptability and feasibility of a new version of the Imaginator intervention, Imaginator 2.0, targeting self-harm behaviour in young people aged 12-25 under mental health services in the UK.
Imaginator 2.0 uses 'functional imagery training', training in individuals to develop and use functional (that is, helpful) mental images to support an alternative behaviour instead of self-harm. Mental imagery is the process of picturing something in the mind, and mental images have strong emotional and motivational characteristics. Functional Imagery Training (FIT) within Imaginator helps young people imagine adaptive behaviours as an alternative to self-harm when dealing with distressing emotions. conditions: Self Injurious Behavior conditions: Adolescent Behavior Problem conditions: Child Behavior Problem conditions: Mental Health Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open ended feasibility and acceptability of novel blended digital psychological intervention primaryPurpose: TREATMENT masking: NONE count: 27 type: ACTUAL name: Imaginator 2.0 measure: Attrition measure: Treatment adherence measure: Scores on User Experience Questionnaire measure: Number of self harm episodes over 3 months measure: Craving Experiences Questionnaire measure: Difficulties in Emotion Regulation Scale measure: Depression, Anxiety, Stress Scale sex: ALL minimumAge: 12 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: West London NHS Trust city: London country: United Kingdom lat: 51.50853 lon: -0.12574 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-04-04 uploadDate: 2024-02-16T12:11 filename: Prot_000.pdf size: 1958833 hasResults: False
nctId: NCT06311071 id: IR.SUMS.MED.REC.1401.200 briefTitle: The Predictive Value of Coronary Artery Calcium Score overallStatus: COMPLETED date: 2022-01-01 date: 2023-05-01 date: 2023-09-01 date: 2024-03-15 date: 2024-03-22 name: Shiraz University of Medical Sciences class: OTHER briefSummary: In this analytical prospective study 498 patients over 40 years with any cardiovascular symptoms and without pre-established coronary artery disease ( CAD) were enrolled. Patients underwent CT scans to measure coronary artery calcium score (CACS), and total calcium scores were recorded. Then, conventional coronary angiography was performed for all the participants as the gold standard for diagnosing CAD (defined as at least one stenotic coronary artery with ≥ 50%). Framingham risk score (FRS) was also estimated for all the patients conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 498 type: ACTUAL name: calcium score name: Invasive coronary angiography measure: coronary artery disease measure: coronary calcium score measure: cardiovascular risk score sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Javad Kojuri city: Shiraz state: Fars zip: 7134814336 country: Iran, Islamic Republic of lat: 29.61031 lon: 52.53113 hasResults: False
nctId: NCT06311058 id: PRO00032531 briefTitle: Protein Supplementation After ACL Surgery overallStatus: RECRUITING date: 2024-02-16 date: 2026-12-01 date: 2027-12-01 date: 2024-03-15 date: 2024-04-02 name: The Methodist Hospital Research Institute class: OTHER briefSummary: The purpose of the study is to assess the longitudinal post-operative care effects of protein supplementation on muscle atrophy in the post-operative period following ACL reconstruction. The main outcome will be muscle size/mass as measured using dual energy x-ray absorptiometry (DEXA) scanning. The primary objective is to assess for any beneficial impact of protein supplementation, with implications of standardizing a recommended protocol for protein supplementation after ACL reconstruction.
Secondary outcomes will be to evaluate the survey data from the KOOS JR and Tampa Scale surveys, as well as functional measures recorded during physical therapy. conditions: ACL Reconstruction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects are randomized to 1 of 3 intervention groups primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE maskingDescription: This is a double-blinded randomized controlled trial. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Whey protein isolate name: Protein + BAA name: Placebo measure: Muscle mass measure: Patient Reported Outcomes measure: Patient Reported Outcomes sex: ALL minimumAge: 16 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Houston Methodist status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Haley Goble, MHA role: CONTACT phone: 713-441-3930 email: hmgoble@houstonmethodist.org name: Robert A Jack, MD role: SUB_INVESTIGATOR name: Patrick C McCulloch, MD role: PRINCIPAL_INVESTIGATOR name: David M Lintner, MD role: SUB_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06311045 id: 23-01469 briefTitle: Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-06 date: 2028-12 date: 2024-03-15 date: 2024-03-15 name: NYU Langone Health class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA. conditions: Obstructive Sleep Apnea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 206 type: ESTIMATED name: N-acetylcysteine (NAC) name: Placebo name: Positive Airway Pressure (PAP) Therapy measure: Percent Change in Overnight Levels of Glutathione (GSH) measure: Mean Change in Pre- to Post-Sleep GSH Levels measure: Mean Change in Pre- to Post-Sleep GSH Levels measure: Ratio of GSH to oxidized GSH (GSSG) (GSH:GSSG) measure: Ratio of GSH to oxidized GSH (GSSG) (GSH:GSSG) measure: 8-Isoprostane Level measure: 8-Isoprostane Level measure: Plasma Nitrate Level measure: Plasma Nitrate Level measure: Plasma Nitrite Level measure: Plasma Nitrite Level measure: Organic Nitrite Level measure: Organic Nitrite Level measure: Interleukin 6 (IL-6) Level measure: Interleukin 6 (IL-6) Level measure: Tumor Necrosis Factor-alpha (TNFα) Receptor-1 (TNFα-R1) Level measure: Tumor Necrosis Factor-alpha (TNFα) Receptor-1 (TNFα-R1) Level measure: Tumor Necrosis Factor-alpha (TNFα) Receptor-2 (TNFα-R2) Level measure: Tumor Necrosis Factor-alpha (TNFα) Receptor-2 (TNFα-R2) Level measure: Reactive Hyperemia Index (RHI) Score measure: Reactive Hyperemia Index (RHI) Score measure: Epworth Sleepiness Scale (ESS) Score measure: Epworth Sleepiness Scale (ESS) Score measure: Insomnia Severity Index (ISI) Score measure: Insomnia Severity Index (ISI) Score measure: Fatigue Severity Scale (FSS) Score measure: Fatigue Severity Scale (FSS) Score measure: Pittsburgh Sleep Quality Index (PSQI) Score measure: Pittsburgh Sleep Quality Index (PSQI) Score sex: ALL minimumAge: 55 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06311032 id: 22-01227 briefTitle: Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas overallStatus: COMPLETED date: 2023-03-29 date: 2023-06-28 date: 2023-07-28 date: 2024-03-15 date: 2024-03-15 name: NYU Langone Health class: OTHER briefSummary: The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas. conditions: Surgery Risk Assessment studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 72 type: ACTUAL measure: Number of Decisions to Stop Surveillance Imaging measure: Number of Decisions to Continue Surveillance Imaging sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06311019 id: 791572 briefTitle: The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections acronym: Dia2tech overallStatus: RECRUITING date: 2024-02-27 date: 2025-09-01 date: 2026-06-01 date: 2024-03-15 date: 2024-03-15 name: Klavs Würgler Hansen class: OTHER name: Steno Diabetes Center Aarhus, Denmark briefSummary: The aim of the study is to evaluate the effect of a combination of 12 months treatment with CGM (Freestyle Libre 2) with hypo and hyper alert in combination with a smart pen for bolus insulin (NOVOpen6) on HbA1c and time in range (TIR) in T2DM patients with baseline HbA1c \>53 mmol/mol (7. 0%, eAG 8,6 mmol/l) as compared with standard care. conditions: Type 2 Diabetes Treated With Insulin studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 104 type: ESTIMATED name: Continuous glucose monitoring and use of connected insulinpen for bolus insulin measure: Change in Haemoglobin A1c measure: Change Time in range measure: Change in Time above range measure: Change in Time below range measure: Mean glucose measure: Standard deviation measure: Change in CV measure: Change in Time with rapid glucose change measure: Change in ARRC measure: Fraction of patients with increased number of bolus insulin per day measure: Fingerprick glucose measurement measure: Glucose views on mobile phone measure: Use of Novopen 6 memory function measure: WHO-5 measure: Diabetes Distress Scale measure: Revised short form of hypoglycaemia Fear Survey measure: eHealth literacy questionnaire (eHLQ), measure: The Glucose Monitoring Satisfaction Questionnaire measure: Diabetes Treatment Satisfaction Questionnaire (DTSQ) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Steno Diabetes Center Aarhus status: NOT_YET_RECRUITING city: Aarhus zip: 8000 country: Denmark name: Katrine B Gørlitz, MD role: CONTACT phone: +45 24210787 email: KAGOER@rm.dk name: Søren Gregersen, Professor role: CONTACT phone: +45 30134245 email: soeren.gregersen@aarhus.rm.dk lat: 56.15674 lon: 10.21076 facility: Regional Hospital Silkeborg, Central Jutland Hospital status: RECRUITING city: Silkeborg zip: 8600 country: Denmark name: Katrine B Gørlitz, MD role: CONTACT phone: +45 24210787 email: KAGOER@rm.dk name: Klavs W Hansen, Professor role: CONTACT phone: +45 78417847 email: klavhans@rm.dk lat: 56.1697 lon: 9.54508 hasResults: False
nctId: NCT06311006 id: K170103J id: 2019-A02579-48 type: OTHER domain: ANSM briefTitle: Safety Registry of a Fecal Microbiota Transplant Cohort acronym: COSMIC-FMT overallStatus: RECRUITING date: 2021-01-04 date: 2029-01-04 date: 2029-01-04 date: 2024-03-15 date: 2024-03-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection. The use of fecal microbiota transplantation (FMT), FMT appears in the most recent European and North American recommendations.
There is no cohort or multicenter registry in France prospectively collecting FMTs, the methods used, their efficacy and side effects. Likewise, there is no prospective collection focused on the cohort of stool donors. A large national cohort of patients who have undergone FMT as part of routine care as well as donors, is essential for evaluating the safety of FMT. conditions: Clostridium Difficile Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 305 type: ESTIMATED measure: Proportion of hospitalizations attributable to FMT measure: Proportion of Clostridium difficile relapses measure: Proportion of relapse measure: Proportion of reinfections measure: Efficacy of FMT in CDI (defined as free from relapse) at 10 weeks and 3 years according to clinical characteristics of donors measure: Efficacy of FMT in CDI (defined as free from relapse) at 10 weeks and 3 years according to clinical characteristics of patients measure: Efficacy of FMT in CDI (defined as free from relapse) at 10 weeks and 3 years according to the method of preparation and administration of fecal preparation measure: Evolution of transit (i.e. number of stools per day and their consistency) and mean BMI in patients Correlation between the evolution of transit and the BMI of the donor and the patient. measure: Patient status (absence of recurrence or relapse or re-infection) according to the composition of the microbiota (by sequencing or metabolomic method or culture) of the donors. measure: Composition of the patient's microbiota before FMT and at week 10 and composition of the donor's microbiota (by sequencing or metabolomic method or culture) of the raw stool and the preparation to be administered to the patient. measure: adverse event rate measure: Metabolomic, immunological analysis (phenotype of peripheral blood immune cells) of the donor and the patient before and after FMT (at W10). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gastroenterology Department of Saint Antoine Hospital status: RECRUITING city: Paris zip: 75012 country: France name: Harry SOKOL, MD, PhD role: CONTACT phone: 0033 1 49 28 31 62 phoneExt: +33 email: harry.sokol@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06310993 id: STH22549 briefTitle: Exercise to Boost Immunity in Advanced Cancer acronym: BICEP overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-03-01 date: 2026-03-01 date: 2024-03-15 date: 2024-03-15 name: Sheffield Teaching Hospitals NHS Foundation Trust class: OTHER name: University of Sheffield name: Sheffield Hallam University briefSummary: The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression conditions: Mesothelioma; Lung conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Exercise measure: Primary Outcome Measure measure: Secondary outcome 1 measure: Secondary Outcome 2 measure: Secondary Outcome 3 measure: Secondary Outcome 4 measure: Secondary Outcome 5 measure: Secondary Outcome 6 measure: Secondary Outcome 7 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Research Centre at Weston Park Hospital city: Sheffield state: England zip: S1O 2SJ country: United Kingdom lat: 53.38297 lon: -1.4659 facility: Sheffield Hallam University city: Sheffield state: South Yorkshire zip: S10 2BP country: United Kingdom lat: 53.38297 lon: -1.4659 hasResults: False
nctId: NCT06310980 id: SMARTPEN briefTitle: Pilot Study to Verify Effect of Smartpen Coordinated With Glucose Sensor. acronym: SMARTPEN overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-07-01 date: 2025-04-01 date: 2024-03-15 date: 2024-03-15 name: Giulio Frontino class: OTHER briefSummary: The Aim of this interventional study in to assess the effect of the use of a smartpen connected by an APP to continuous glucose sensors in a cohort of diabetic adolescents in not good metabolic control.
Primary endpoint: time in range Secondary endpoints: other glucometrics, Hba1c, treatment satisfaction. conditions: Diabetes Mellitus, Type 1 studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 34 type: ESTIMATED name: smartpen measure: Time in range measure: time below range measure: time above range measure: coefficient of variation (CV) measure: HbA1c measure: ITSRQ measure: DIDS sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06310967 id: IG3018-23-02-01 briefTitle: A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-06 date: 2025-06 date: 2024-03-15 date: 2024-03-15 name: Intelligem Therapeutics Australia Pty Ltd. class: INDUSTRY briefSummary: This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD. conditions: Hyperuricemia conditions: Hypouricemia, Renal studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Part 1 is a randomized, double-blind, placebo-controlled study where the doses of the study drug are escalated in a predesigned manner in 3 cohorts.
Initiation Dose shall be at 0.25 g tablets (Cohort A) and doses are escalated to 0.5 g (Cohort B) and then to 1.0 g (Cohort C) in a planned manner. Each cohort will have 10 eligible patients. Randomization will be performed in Part 1 and as per the randomization code, 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort. A total of 30 subjects are planned to be enrolled.
Part 2 is an open-label proof of concept study involving hyperuricemia subjects with advanced predialysis CKD (Stage 3A, Stage 3B and Stage 4), and treated with two doses \[0.5 g BID IG3018 (Cohort D) and 1.0 g BID IG3018 (Cohort E)\] . At least 5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in each dose and will receive the determined study dose of IG3018 twice daily (BID) for 4 weeks. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Part 1 is a randomized, double-blind, placebo-controlled study. For each dose cohort in Part 1, the Sponsor, subjects and other personnel involved with the conduct of the study will be blinded to the study products.
Part 2 is an open-label proof of concept study. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 46 type: ESTIMATED name: IG3018 name: Placebo matching IG3018 measure: Safety Assessments (Part 1 and Part 2) measure: The proportions of change from baseline in serum uric acid to normal level (≤ 0.36 mmol/L) (Part 1 and Part 2) measure: The proportions of change from baseline in serum uric acid to ≤ 0.30 mmol/L and ≤ 0.24 mmol/L respectively (Part 1 and Part 2) measure: The actual change of serum uric acid (Part 1 and Part 2) measure: The percentage change of serum uric acid (Part 1 and Part 2) measure: Gouty Attacks (Part 1 and Part 2) measure: Urinary Albumin/Creatinine Ration (U-ACR) (Part 2 only) measure: Ae of IG3018 (Part 1 only) measure: Cmax of IG3018 (Part 1 only) measure: Tmax of IG3018 (Part 1 only) measure: T1/2 of IG3018 (Part 1 only) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False